RM-NBS / Neurobehavioural and neuroendocrine signalling
Ziconotide
Also known as: SNX-111 · Synthetic omega-conotoxin MVIIA
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Ziconotide is a synthetic analog of a cone-snail peptide with three disulfide bridges. Its labeled finished product is an intrathecal formulation with route-specific controls.
Evidence position
The FDA label and randomized human evidence support Grade A for that exact presentation.
What the record does not establish
The evidence cannot be generalized to an unlabeled route, a different formulation or an unverified sample.
Sources
- 01Prialt prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- Current U.S. label, molecular description and boxed warning
- Does not show
- Specific to a preservative-free intrathecal finished product
- 02Randomized controlled intrathecal ziconotide trialPubMed
- Shows
- Controlled human trial of a defined intrathecal presentation
- Does not show
- Route-specific clinical evidence, not material testing
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Ziconotide
- CID
- 16135415
- Formula
- C102H172N36O32S7
- Mass
- 2639.2
PUBMED / FOUND RECORDS
- The Diagnosis and Treatment of Neuropathic Pain.Deutsches Arzteblatt international / 2024 Dec 13PMID 39475707 / DOI 10.3238/arztebl.m2024.0215
- Ziconotide. / 2006PMID 37247359
- Ziconotide.CNS drugs / 2006PMID 16599651 / DOI 10.2165/00023210-200620040-00007
- Ziconotide.Journal of pain & palliative care pharmacotherapy / 2014 MarPMID 24397285 / DOI 10.3109/15360288.2013.864749
- Ziconotide. / 2026 JanPMID 29083772
CLINICALTRIALS.GOV / FOUND RECORDS
- Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With CancerUNKNOWN / PHASE2 / National Cancer Institute, NaplesNCT00996983 / DIRECT intervention MATCH: Ziconotide
- Intrathecal Bolus Doses of ZiconotideCOMPLETED / PHASE4 / University Hospital, LinkoepingNCT01373983 / DIRECT intervention MATCH: Ziconotide
- A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic PainCOMPLETED / PHASE2 / NeurexNCT00002160 / DIRECT intervention MATCH: Ziconotide
- OP2C : Prialt® Observatory in Clinical PracticeRECRUITING / NO PHASE / Institut Cancerologie de l'OuestNCT04321408 / DIRECT intervention MATCH: Ziconotide
- Single Shot Intrathecal Ziconotide for Painful Neuropathy or MyelopathyWITHDRAWN / PHASE4 / Aaron BosterNCT01992562 / DIRECT intervention MATCH: Ziconotide